Bispecific anti-CD40×CLDN18.2 antibody and its use

A bispecific antibody targeting CD40 and CLDN18.2 with reduced cross-linking effects addresses hepatotoxicity issues, enabling selective tumor cell killing and improving therapeutic index in cancer treatment.

DE112022005674T5Pending Publication Date: 2024-11-14ANHUI RUBIOX VISION BIOTECH
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
DE112022005674
Authority / Receiving Office
DE · DE
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-30
Filing Date
2022-12-28
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Existing agonistic antibodies targeting CD40 cause dose-limiting toxicity, particularly hepatotoxicity, due to nonspecific activation of CD40-expressing immune cells on hepatocytes, limiting their therapeutic index in cancer treatment.

Method used

Development of a bispecific antibody that specifically targets CD40 and CLDN18.2, utilizing a single structure domain antibody (VHH) with modifications to reduce cross-linking effects, such as the FcγRIIb-dependent cross-linking, to achieve selective activation of immune cells at tumor sites without causing hepatotoxicity.

Benefits of technology

The bispecific antibody achieves high-intensity activation of immune cells at tumor sites, effectively killing tumor cells while minimizing adverse events like hepatotoxicity, thereby enhancing therapeutic efficacy and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000029_0000
    Figure 00000029_0000
  • Figure 00000029_0001
    Figure 00000029_0001
  • Figure 00000030_0000
    Figure 00000030_0000
Patent Text Reader

Abstract

A bispecific antibody targeting both CD40 and CLDN18.2 is provided; furthermore, a pharmaceutical composition comprising the bispecific antibody, a use for the treatment of related diseases, and a treatment procedure are provided.
Need to check novelty before this filing date? Find Prior Art

Description

Background technology

[0001] CD40 is a co-stimulatory protein with a molecular mass of 50 kDa, located on the surface of cell membranes and belonging to the tumor necrosis factor receptor (TNFR) family. It is constitutively expressed in antigen-presenting cells (including dendritic cells, B cells, monocytes, and macrophages) as well as in a variety of other cells, e.g., endothelial cells, fibroblasts, and thymic epithelial cells. Furthermore, CD40 has been found to be expressed in a variety of tumor cells (e.g., chronic lymphocytic leukemia, multiple myeloma, kidney cancer, lung cancer, etc.). CD40 forms a trimer on the cell surface, and the corresponding ligand, CD40L (i.e., CD154), is predominantly expressed on the surface of activated T cells. The interaction of CD40 and CD40L signals the co-stimulation of T-cell activation.The binding of CD40L to CD40 on T cells can activate several signaling pathways, including the NF-κB (nuclear factor-κB) signaling pathway.

[0002] Although agonistic antibodies targeting CD40, such as selicrelumab, dacetuzumab, and APX005, have demonstrated clinical activity in clinical trials across a variety of indications, these agonistic antibodies have been associated with adverse events of dose-limiting toxicity (Hassan SB et al. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol 2014; 36:96-104). The most significant adverse event to date is hepatotoxicity, in which these agonistic antibodies non-specifically activate CD40-expressing immune cells on the surface of hepatocytes, leading to hepatotoxicity and reducing the therapeutic index.

[0003] The human CLDN18 gene has two distinct exons 1 that are transcribed and variably spliced ​​to ultimately generate two protein isoforms, CLDN18.1 and CLDN18.2, which differ only at the N-terminus. Both CLDN18 isoforms consist of 261 amino acids and have four transmembrane structural domains, but are distributed in different tissues, with CLDN18.1 being expressed primarily in lung tissue and CLDN18.2 only in differentiated epithelial cells of the gastric mucosa and not in gastric stem cells (Sahin, Ugur, et al. “Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development.” ClinicalCancer Research 14.23 (2008): 7624-7634). CLDN18.2 is highly expressed in a variety of tumor tissues such as non-small cell lung cancer (25%), gastric cancer (70%), pancreatic cancer (50%) and esophageal cancer (30%), but is hardly expressed in normal tissues (Kumar, V., et al. (2018).“Emerging Therapies in the Management of Advanced-Stage Gastric Cancer”, Front Pharmacol 9: 404) and is now, due to its different expression in tumor cells and normal tissue, a very promising target for the effect of antitumor drugs.

[0004] Therefore, there is an urgent need to develop a bispecific antibody that targets CLDN18.2 and CD40 to specifically kill tumor cells without causing adverse events such as hepatotoxicity, and which offers more options for cancer treatment. Summary of the invention

[0005] The present invention discloses a novel bispecific antibody targeting both CD40 and CLDN18.2, a polynucleotide encoding the bispecific antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a method for using the bispecific antibody to treat a disease associated with CD40 and / or CLDN18.2, and a use of the bispecific antibody for the individualized treatment, prevention, and / or diagnosis of diseases associated with CD40 and / or CLDN18.2. The bispecific antibody is capable of achieving specific, high-intensity activation of immune cells at focal sites and low agonistic activity at sites such as hepatocytes that cannot form a cross-linking effect, thereby achieving specific killing of tumor cells without causing undesirable events such as hepatotoxicity.

[0006] In a first aspect, the present invention provides a bispecific antibody (bispecific anti-CD40×CLDN18.2 antibody) that specifically binds CD40 and CLDN18.2, comprising (i) an anti-CD40 antibody or a fragment thereof and (ii) an anti-CLDN18.2 antibody or a fragment thereof. In one embodiment, the anti-CLDN18.2 antibody or fragment thereof is a single-structure domain antibody (VHH).

[0007] In one embodiment, the present invention provides a bispecific anti-CD40×CLDN18.2 antibody comprising the following: (i) a heavy chain with the structure VH-CH1-Fc-VHH, and (ii) a light chain with the structure VL-CL, wherein the combination of VH and VL forms a first antigen-binding part that binds specifically to CD40, and VHH forms a second antigen-binding part that binds specifically to CLDN18.2, and optionally VHH is connected to Fc via an adapter.

[0008] In one embodiment, the present invention provides a bispecific anti-CD40×CLDN18.2 antibody comprising the following: (i) a heavy chain with the structure VH-CH1-Fc-VHH, and (ii) a light chain with the structure VL-CL, wherein The VH comprises three heavy chain CDRs as contained in SEQ ID NO:11, the VL comprises three light chain CDRs as contained in SEQ ID NO:10, and the VHH comprises three CDRs as contained in SEQ ID NO:18; The VH comprises three heavy chain CDRs as contained in SEQ ID NO:12, the VL comprises three light chain CDRs as contained in SEQ ID NO:10, and the VHH comprises three CDRs as contained in SEQ ID NO:18; The VH comprises three heavy chain CDRs, as contained in SEQ ID NO:13; the VL comprises three light chain CDRs, as contained in SEQ ID NO:10; and the VHH comprises three CDRs, as contained in SEQ ID NO:18; or The VH comprises three heavy chain CDRs as contained in SEQ ID NO:14, the VL comprises three light chain CDRs as contained in SEQ ID NO:10, and the VHH comprises three CDRs as contained in SEQ ID NO:18.

[0009] In another embodiment, the present invention provides a bispecific anti-CD40×CLDN18.2 antibody comprising the following: (i) a heavy chain with the structure VH-CH1-Fc-VHH, and (ii) a light chain with the structure VL-CL, wherein The VH comprises three heavy chain CDRs, as shown in SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6; the VL comprises three light chain CDRs, as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3; and the VHH comprises three CDRs, as shown in SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17; The VH comprises three heavy chain CDRs, as shown in SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7; the VL comprises three light chain CDRs, as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3; and the VHH comprises three CDRs, as shown in SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17; The VH comprises three heavy chain CDRs, as shown in SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:8; the VL comprises three light chain CDRs, as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3; and the VHH comprises three CDRs, as shown in SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17; or The VH comprises three heavy chain CDRs, as shown in SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:9; the VL comprises three light chain CDRs, as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3; and the VHH comprises three CDRs, as shown in SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17.

[0010] In a further embodiment, the present invention provides a bispecific anti-CD40×CLDN18.2 antibody comprising the following: (i) a heavy chain with the structure VH-CH1-Fc-VHH, and (ii) a light chain with the structure VL-CL, wherein The VH comprises a sequence from the three CDRs of the heavy chain contained in SEQ ID NO:11, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:11; the VL comprises a sequence from the three CDRs of the light chain contained in SEQ ID NO:10, and the sequence exhibits at least 90%, 91%, 92%, 93%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:10; the VHH comprises a sequence from the three CDRs contained in SEQ ID NO:18, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, 99% or more sequence identity with SEQ ID NO:18 on; The VH comprises a sequence from the three CDRs of the heavy chain contained in SEQ ID NO:12, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:12; the VL comprises a sequence from the three CDRs of the light chain contained in SEQ ID NO:10, and the sequence exhibits at least 90%, 91%, 92%, 93%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:10; the VHH comprises a sequence from the three CDRs contained in SEQ ID NO:18, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, 99% or more sequence identity with SEQ ID NO:18 on; The VH comprises a sequence from the three CDRs of the heavy chain contained in SEQ ID NO:13, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:13; the VL comprises a sequence from the three CDRs of the light chain contained in SEQ ID NO:10, and the sequence exhibits at least 90%, 91%, 92%, 93%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:10; the VHH comprises a sequence from the three CDRs contained in SEQ ID NO:18, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, 99% or more sequence identity with SEQ ID NO:18; or The VH comprises a sequence from the three CDRs of the heavy chain contained in SEQ ID NO:14, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:14; the VL comprises a sequence from the three CDRs of the light chain contained in SEQ ID NO:10, and the sequence exhibits at least 90%, 91%, 92%, 93%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:10; the VHH comprises a sequence from the three CDRs contained in SEQ ID NO:18, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, 99% or more sequence identity with SEQ ID NO:18.

[0011] In one embodiment, the present invention provides a bispecific anti-CD40×CLDN18.2 antibody comprising the following: (i) a heavy chain with the structure VH-CH1-Fc-VHH, and (ii) a light chain with the structure VL-CL, wherein The VH comprises a sequence as shown in SEQ ID NO:11, the VL comprises a sequence as shown in SEQ ID NO:10, and the VHH comprises a sequence as shown in SEQ ID NO:18; The VH comprises a sequence as shown in SEQ ID NO:12, the VL comprises a sequence as shown in SEQ ID NO:10, and the VHH comprises a sequence as shown in SEQ ID NO:18; The VH comprises a sequence as shown in SEQ ID NO:13, the VL comprises a sequence as shown in SEQ ID NO:10, and the VHH comprises a sequence as shown in SEQ ID NO:18; or The VH comprises a sequence as shown in SEQ ID NO:14, the VL comprises a sequence as shown in SEQ ID NO:10, and the VHH comprises a sequence as shown in SEQ ID NO:18.

[0012] In each of the above-mentioned embodiments, the single-structure domain antibody (VHH) in the bispecific anti-CD40×CLDN18.2 antibody of the present invention is a Kamelidae VHH, a partially or fully humanized VHH, or a chimeric VHH.

[0013] In each of the above-mentioned embodiments, the VHH of the bispecific anti-CD40×CLDN18.2 antibody of the present invention is connected to the Fc via an adapter, wherein the adapter may be any flexible sequence known or to become available in the future, typically a short flexible amino acid sequence, and in one specific embodiment the adapter is (G4S)n, where n is an integer equal to or greater than 1, for example, n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9; GGGSG; GGSGG; GSGGG; SGGGG; GGTGS; GTSPGG; GNGGGS; G4S-GSGGG-G4S-SGGGG; GGG; DGGGS; TGEKP; GGRR; EGKSSGSGSESKVD; KESGSVSSEQLAQFRSLD; GGRRGGGS; LRQRDGERP; LRQKDGGGSERP; GSTSGSGKPGSGEGSTKG, and the like. In a specific embodiment, the adapter is selected from (G4S)3.

[0014] In each of the embodiments mentioned above, the Fc region of the bispecific anti-CD40×CLDN18.2 antibody of the present invention can be selected from the natural Fc region of any prior art antibody of the IgG class, such as a common or germline IgG Fc region. In one specific embodiment, the IgG Fc regions can be Fc regions of different IgG subclasses, such as Fc regions of IgG1, IgG2, IgG3, and IgG4. In another specific embodiment, the IgG Fc region is an Fc sequence of IgG1. In another embodiment, the IgG Fc region can have mutations / modifications to achieve a stabilizing antibody effect or to attenuate the FcγRIIb-dependent crosslinking effect to avoid hepatotoxicity, as known from the prior art. In one specific embodiment, the bispecific anti-CD40×CLDN18 is used.The 2-antibody of the present invention is modified such that it comprises a constant region without cross-linking effects. For example, the FcγRIIb-dependent cross-linking effect of the bispecific anti-CD40×CLDN18.2 antibody of the present invention can be reduced or eliminated by mutation of residue N297, the glycosylation site in the Fc region, to Gly, Ala, Gln, Asp, or Glu. In a preferred embodiment, the Fc region of the bispecific anti-CD40×CLDN18.2 antibody of the present invention includes the N297Q mutation to reduce binding to the Fc receptor.

[0015] In one embodiment, the constant structural domain CL of the light chain of the bispecific anti-CD40×CLDN18.2 antibody of the present invention is derived from k or λ.

[0016] In one embodiment, the present invention provides a bispecific anti-CD40×CLDN18.2 antibody comprising the following: (i) a heavy chain with the structure VH-CH1-Fc-VHH, and (ii) a light chain with the structure VL-CL, wherein The heavy chain comprises a sequence of the three heavy chain CDRs contained in SEQ ID NO:19 and the three CDRs contained in VHH, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:19; the light chain comprises a sequence of the three light chain CDRs contained in SEQ ID NO:23, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:23; The heavy chain comprises a sequence of the three heavy chain CDRs contained in SEQ ID NO:20 and the three CDRs contained in VHH, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:20; the light chain comprises a sequence of the three light chain CDRs contained in SEQ ID NO:23, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:23; The heavy chain comprises a sequence of the three heavy chain CDRs contained in SEQ ID NO:21 and the three CDRs contained in VHH, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:21; the light chain comprises a sequence of the three light chain CDRs contained in SEQ ID NO:23, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:23; or The heavy chain comprises a sequence of the three heavy chain CDRs contained in SEQ ID NO:22 and the three CDRs contained in VHH, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:22. The light chain comprises a sequence of the three light chain CDRs contained in SEQ ID NO:23, and the sequence exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:23.

[0017] In one embodiment, the present invention provides a bispecific anti-CD40×CLDN18.2 antibody comprising the following: (i) a heavy chain with the structure VH-CH1-Fc-VHH, and (ii) a light chain with the structure VL-CL, wherein The heavy chain comprises a sequence as shown in SEQ ID NO:19 and the light chain comprises a sequence as shown in SEQ ID NO:23; The heavy chain comprises a sequence as shown in SEQ ID NO:20 and the light chain comprises a sequence as shown in SEQ ID NO:23; The heavy chain comprises a sequence as shown in SEQ ID NO:21, and the light chain comprises a sequence as shown in SEQ ID NO:23; or The heavy chain comprises a sequence as shown in SEQ ID NO:22 and the light chain comprises a sequence as shown in SEQ ID NO:23.

[0018] In one embodiment, the bispecific anti-CD40×CLDN18.2 antibody of the present invention is able to enhance an immune response to an antigen and to induce antibody-dependent cytotoxicity against CD40-expressing cells (e.g., CD40-expressing tumor cells) and against CLDN18.2-expressing cells (e.g., CLDN18.2-expressing tumor cells).

[0019] In a second aspect, the present invention also provides polynucleotides (nucleic acids) encoding a bispecific anti-CD40×CLDN18.2 antibody of the present invention, as well as vectors comprising these polynucleotides, preferably expression vectors.

[0020] In a third aspect, the present invention provides host cells containing a polynucleotide or a vector of the present invention. The host cells can be prokaryotic and eukaryotic cells commonly used in the industry.

[0021] In a fourth aspect, the present invention provides a method for generating a bispecific anti-CD40×CLDN18.2 antibody of the present invention, comprising the following steps: (i) cultivating a host cell of the present invention under conditions suitable for the expression of a bispecific anti-CD40×CLDN18.2 antibody of the present invention, and optionally (ii) obtaining the bispecific anti-CD40×CLDN18.2 antibody of the present invention.

[0022] In a fifth aspect, the present invention provides an immunoconjugate, a kit, a pharmaceutical composition, a combination product, or an article comprising a bispecific anti-CD40×CLDN18.2 antibody of the present invention. In one embodiment, the pharmaceutical composition, combination product, or article provided by the present invention further comprises other therapeutic agents and optionally pharmaceutical excipients; preferably, the other therapeutic agents are selected from chemotherapeutic agents and cytotoxic agents.

[0023] In a sixth aspect, the present invention provides for the use of the bispecific anti-CD40×CLDN18.2 antibodies, immunoconjugates, kits, pharmaceutical compositions, combination products, or articles of the present invention for the treatment, prevention, and / or diagnosis of diseases associated with CD40 and those associated with CLDN18.2. In one embodiment, the CD40-associated disease is, for example, a cancer with abnormal CD40 expression. In another embodiment, the CLDN18.2-associated disease is, for example, a cancer in which CLDN18.2 is abnormally expressed.

[0024] In one embodiment, the present invention provides for the use of a bispecific anti-CD40×CLDN18.2 antibody, a polynucleotide, a vector, a host cell, an immunoconjugate, a kit, a pharmaceutical composition, a combination product or an article, as described in the first to third aspects and the fifth aspect, in the manufacture of a drug, wherein the drug is for the treatment, prevention and / or diagnosis of a CD40-associated disease, a CLDN18.2-associated disease.

[0025] In a seventh aspect, the present invention provides a method for treating a CD40-associated disease and a method for treating a CLDN18.2-associated disease, comprising administering a therapeutically effective amount of a bispecific anti-CD40×CLDN18.2 antibody of the present invention or of an immunoconjugate, pharmaceutical composition, combination product, or article of the present invention to a patient who requires it. In one embodiment, the CD40-associated disease is, for example, a cancer with abnormal CD40 expression. In another embodiment, the CLDN18.2-associated disease is, for example, a cancer in which CLDN18.2 is abnormally expressed. Short description of the drawings Figs. Figure 1 shows a schematic structure of a bispecific antibody of the present invention. Figs.Figure 2 shows the binding activity of the bispecific antibody of the present invention to P17-His fusion protein. Figs. Figure 3 shows the binding activity of the bispecific antibodies of the present invention to huCD40-CHO-K cells. Figs. Figure 4 shows the binding activity of the bispecific antibodies of the present invention on 18.2-HEK293 cells. Figs. Figures 5A-5B show the activation of the CD40 signaling pathway by the bispecific antibody of the present invention in the presence (5A) or absence (5B) of a crosslinker. Figs. Figures 6A-6B show the activation of the CD40 signaling pathway by the bispecific antibody of the present invention when CLDN18.2 is expressed on the cell surface (6A) or when CLDN18.2 is not expressed (6B). Figs. Figure 7 shows the inhibitory effect of the bispecific antibodies of the present invention on tumor growth in humanized mice. Figs. Figures 8A-8D show the results of the investigation into whether the bispecific antibodies of the present invention cause hepatotoxicity in vivo in humanized mice. Detailed description of the invention 1. Definition

[0026] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as they are commonly understood by a person skilled in the art in the field to which the present invention belongs. All publications, patent applications, patents, and other references cited herein are incorporated by reference in their entirety. Furthermore, the materials, methods, and examples described herein are for illustrative purposes only and are not intended to be limiting. Further features, subject matter, and advantages of the present invention will become apparent from this description and the accompanying drawings, as well as from the accompanying claims.

[0027] The following definitions are used for the interpretation of this description, and where appropriate, terms used in the singular may also include the plural and vice versa. It should be understood that the terms used here serve only to describe certain embodiments and are not to be understood as restrictive.

[0028] The term "approximately", when used in conjunction with numerical values, is intended to cover numerical values ​​within a range whose lower limit is 10 percent below the stated numerical value and whose upper limit is 10 percent above the stated numerical value.

[0029] The term “and / or” used here means one of the options or two or more of the options.

[0030] As used herein, the terms "contain" or "comprise" are intended to include the described elements, integers, or steps, but not to exclude any other elements, integers, or steps. When used herein, the terms "contain" or "comprise" also refer to combinations of the described elements, integers, or steps, unless otherwise specified. For example, when a variable antibody region is referred to as "containing" a specific sequence, this means that it also includes variable antibody regions composed of that specific sequence.

[0031] The term "antibody" is used here in its broadest sense and refers to a protein containing an antigen-binding site, and includes natural and artificial antibodies with various structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), single-chain antibodies, single-structure domain antibodies, intact antibodies, and antibody fragments. Preferably, the antibodies of the present invention are single-structure domain antibodies or heavy-chain antibodies.

[0032] The term "antibody fragment" refers to a molecule that differs from an intact antibody, contains a portion of the intact antibody, and is capable of binding the antigen bound by the intact antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; Bis antibodies; linear antibodies; single-chain antibodies (e.g., scFv); single-structure domain antibodies; bivalent or bispecific antibodies or fragments thereof; Camelidae antibodies (heavy-chain antibodies); and bispecific or multispecific antibodies formed from antibody fragments.

[0033] The term "Fc region" includes at least part of the constant region. It encompasses Fc regions with the natural sequence and Fc regions with variants. In some embodiments, the Fc region of the human IgG heavy chain extends from Cys226 or Pro230 to the carbonyl end of the heavy chain. However, lysine (Lys447) at the C-terminus of the Fc region may or may not be present. Unless otherwise specified, the numbering of amino acid residues in the Fc region or the constant region is based on the EU numbering system, also known as the EU index.

[0034] The term “variable region” or “variable structural domain” refers to the structural domains of an antibody’s heavy or light chain that are involved in the binding of the antibody to the antigen. The variable structural domains of the heavy and light chains of natural antibodies generally have a similar structure, with each structural domain containing four conserved framing regions (FRs) and three complementarity-determining regions (CDRs) (see, e.g., Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p. 91 (2007)). A single VH or VL structural domain may be sufficient to ensure antigen-binding specificity.

[0035] The complementarity-determining region, or CDR region, is the region of the variable structural domain of an antibody that is highly variable in its sequence and forms a structurally defined loop (hypervariable loop) and / or contains antigenic contact residues (antigenic contacts). CDRs are primarily responsible for binding to antigenic epitopes. The heavy chain CDRs are usually designated CDR1, CDR2, and CDR3 and are numbered consecutively from the N-terminus. For a given amino acid sequence of the variable heavy chain region, the precise amino acid sequence boundaries of each CDR can be determined using one of the many known antibody CDR assignment systems or combinations thereof, where the assignment systems are based, for example, on the three-dimensional structure of the antibody and the topology of the CDR ring (Chothia et al. (1989) Nature 342: 877-883, Al-Lazikani et al.).“Standard conformations for the canonical structures of immunoglobulins”. Journal of Molecular Biology, 273, 927-948 (1997)), Kabat based on the variability of antibody sequences (Kabat et al, Sequences of Proteins of Immunological Interest, 4th ed., US Dept. of Health and Human Services, National Institutes of Health (1987)), AbM (University of Bath), Contact (University College London), International ImMunoGeneTics Database (IMGT) (http: / / imgt.cines.fr / ), and the North CDR definition, which is based on affinity propagation clustering using a large number of crystal structures.

[0036] Unless otherwise specified, the term “CDR” or “CDR sequence” in the present invention includes a CDR sequence determined by any of the above-mentioned methods.

[0037] The CDR can also be determined based on the same AbM numbering position as a reference CDR sequence (e.g., one of the example CDRs of the present invention). In one embodiment, the position of the CDR of an antibody of the present invention is determined based on the AbM numbering scheme.

[0038] Unless otherwise specified, in the present invention the positions of the residues (including the residues of the variable region of the heavy chain) in the variable regions of the antibodies and the CDRs are referred to the numbering positions according to the AbM numbering system.

[0039] The term “single-structure domain antibody” generally refers to an antibody in which a single variable structural domain (e.g., a heavy-chain variable domain (VH), a light-chain variable domain (VL), a heavy-chain variable domain derived from the heavy chain of a Camelidae antibody, or a VH-like single-structure domain (v-NAR) derived from a fish IgNAR) is capable of conferring antigen binding. That is, the single variable structural domain does not need to interact with another variable structural domain to recognize the target antigen. Examples of single-structure domain antibodies include those derived from Camelidae (camelids and llamas) and chondrichthyens (e.g., nurse sharks) (WO 2005 / 035572).Single-structure domain antibodies derived from Kamelidae, also referred to as VHH in the present application, consist of only one variable region of the heavy chain and are antibodies containing only one chain FR4-CDR3-FR3-CDR2-FR2-CDR1-FR1 from the C-terminus to the N-terminus, and are also referred to as "nano-antibodies". A single-structure domain antibody is the smallest known unit that can bind a target antigen.

[0040] The term "multispecific antibody" refers to an antibody with at least two antigen-binding sites, each of which binds to a different epitope of the same antigen or to a different epitope of a different antigen. A multispecific antibody is an antibody that exhibits binding specificity for at least two different antigenic epitopes. In one embodiment, such multispecific antibodies are provided here, exhibiting binding specificity for a first antigen and a second antigen, and are also referred to as "bispecific antibodies".

[0041] The term "immunoconjugate" refers to an antibody that is conjugated with one or more other substances (including, but not limited to, cytotoxic agents or markers).

[0042] The term "agonist" refers to a substance that increases a parameter (e.g., the activity) of a specific molecule (e.g., a co-stimulatory molecule). For example, the term includes substances that increase the activity of a specific molecule (e.g., CD40) by at least 5%, 10%, 20%, 30%, 40%, or more. The agonism does not necessarily have to be 100%.

[0043] In the context of "anti-CD40 antibodies," the term "crosslinking effect" refers to the phenomenon in which an anti-CD40 antibody promotes the local aggregation (multimerization) of more than one anti-CD40 antibody through the binding of the anti-CD40 antibody's Fc molecule to FcγRIIB, which in turn promotes the aggregation of a sufficient number of CD40 molecules. This crosslinking effect triggers downstream intracellular signaling, thereby activating the corresponding CD40-expressing immune cells.

[0044] The term “half-active concentration (EC) 50 )“ refers to the concentration of a drug, antibody or toxin that, after a certain exposure time, produces a 50% response between the baseline and maximum values.

[0045] The term "therapeutic index" (TI) usually refers to the ratio between the semi-lethal dose (LD50) and the total dose of the therapeutic agent. 50 ) and the half-effective dose (ED 50 ) and is an indicator of the safety of a drug.

[0046] The calculation of sequence identity between sequences is performed as follows.

[0047] To determine the percentage identity of two amino acid sequences or two nucleic acid sequences, these sequences are compared for optimal comparison purposes (e.g., zeros can be inserted into one or both of the first and second amino acid or nucleic acid sequences to enable optimal comparison, or non-homologous sequences can be discarded for comparison purposes). In a preferred embodiment, the length of the reference sequence to be compared is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, or 100% of the length of the reference sequence for comparison purposes. Subsequently, the amino acid residues or nucleotides at the corresponding amino acid or nucleotide positions are compared.If a position in the first sequence is occupied by the same amino acid residue or the same nucleotide at the corresponding position in the second sequence, then the molecules at that position are identical.

[0048] Mathematical algorithms can be used to perform sequence comparisons between two sequences and to calculate the percentage identity. In a preferred embodiment, the algorithm of Needlema and Wunsch (1970 J. Mol. Biol. 48:444-453) (available at http: / / www.gcg.com) is used, which has been integrated into the GAP program of the GCG software package, applying either the Blossum-62 matrix or the PAM250 matrix and zero weights 16, 14, 12, 10, 8, 6 or 4 and length weights 1, 2, 3, 4, 5 or 6 to determine the percentage identity between two amino acid sequences. In another preferred embodiment, the percentage identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http: / / www.gcg.com) using the NWSgapdna.CMP matrix and the zero weights 40, 50, 60, 70 or 80 and the length weights 1, 2, 3, 4, 5 or 6.One particularly preferred set of parameters (which should be used unless otherwise specified) is the Blossum 62 scoring matrix, which uses zero penalty 12, zero extension penalty 4, and shifted zero penalty 5.

[0049] The percentage identity between two amino acid sequences or nucleotide sequences can also be determined using the weighted PAM120 residue table, the zero-length penalty 12 and the zero-penalty 4, using the algorithm by E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been integrated into the program ALIGN (edition 2.0).

[0050] Additionally or alternatively, the nucleic acid sequences and protein sequences described here can also be used as "query sequences" for searching public databases to identify, for example, other sequences from family members or related sequences.

[0051] The term "treatment" means the slowing, interruption, reversal, alleviation, termination, reduction, or reversal of the progression or severity of an existing symptom, condition, illness, or disease. Desired therapeutic effects include, but are not limited to, preventing the onset or recurrence of the disease, alleviating symptoms, reducing direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, improving or mitigating the disease condition, and mitigating or improving the prognosis. In some embodiments, the antibodies of the present invention are used to delay the progression of the disease or to slow its rate of progression.

[0052] The term "prophylaxis" encompasses the prevention of the onset or progression of a disease or condition, or the symptoms of a particular disease or condition. In some implementations, participants with a family history of cancer are candidates for prophylactic programs. In the context of cancer, the term "prophylaxis" generally refers to the administration of a drug before the appearance of cancer signs or symptoms, particularly in participants at risk of developing cancer.

[0053] The term "effective amount" refers to such quantity or dose of an antibody, conjugate, or composition of the present invention that, when administered to a patient in a single or multiple doses, produces the desired effect in the patient requiring treatment or prophylaxis. The effective amount can be readily determined by a qualified physician by considering a variety of factors, such as the mammalian species, body weight, age and general health, the specific disease, the extent or severity of the disease, the individual patient's response, the specific antibody administered, the route of administration, the bioavailability properties of the administered agent, the chosen dosage regimen, and the use of concomitant therapies.

[0054] The term "therapeutically effective amount" refers to the quantity that is effective at a desired dose for a desired duration while achieving a desired therapeutic outcome. The therapeutically effective amount of an antibody, antibody fragment, conjugate, or combination thereof can vary depending on a variety of factors, such as the disease state, age, sex, and weight of the individual, as well as the antibody's or antibody fragment's ability to elicit the desired response in that individual. A therapeutically effective amount is also one at which any toxic or harmful effect of the antibody, antibody fragment, or its conjugate or combination is less than any therapeutically beneficial effect. The therapeutically effective amount preferably inhibits a measurable parameter (e.g., tumor growth rate, tumor volume, etc.).) by at least about 20%, preferably by at least about 40%, more preferably by at least about 50%, 60% or 70% and more preferably by at least about 80% or 90% compared to an untreated subject, the ‘therapeutically effective amount’ can be used in an animal model system predicting efficacy in human tumors to evaluate the ability of a compound to inhibit a measurable parameter (e.g. cancer).

[0055] The term "prophylactically effective dose" refers to the amount required to achieve the desired prophylactic effect at the necessary dose and over the required period. Generally, the prophylactically effective dose is lower than the therapeutically effective dose because the prophylactic dose is administered before or at an earlier stage of the disease in the subjects.

[0056] The term "pharmaceutical composition" refers to a composition in a form that allows the biological activity of the active ingredients contained therein to become effective and that does not contain any additional ingredients that are unacceptably toxic to the participant to whom the composition is administered.

[0057] The terms “linker peptide”, “adapter”, or “peptide adapter” are used interchangeably in this application to refer to a peptide comprising one or more linked amino acids, such as small amino acid residues or hydrophilic amino acid residues (e.g., glycine, serine, threonine, proline, aspartic acid, asparagine, etc.). Linker peptides typically consist of amino acids ranging in length from 5 to 50 amino acids, e.g., 10, 15, 20, 25, or 30 amino acids. A person skilled in the art will understand that many commonly used adapters can be employed in embodiments of the present invention.

[0058] The term “CLDN18.2-associated disease” refers to any condition caused, exacerbated, or otherwise associated with abnormal expression (e.g., increased expression) or abnormal activity of CLDN18.2 (e.g., human CLDN18.2). In one embodiment, the CLDN18.2-associated disease is a tumor in which CLDN18.2 (e.g., human CLDN18.2) is abnormally expressed (e.g., increased expression).

[0059] The term “CD40-associated disease” refers to any condition that is caused, exacerbated, or otherwise associated with abnormal expression (e.g., increased expression) or activity of CD40. In one embodiment, a CD40-associated disease is a tumor in which CD40 is abnormally expressed (e.g., increased expression).

[0060] The terms "individual" and "participant" are used interchangeably and include mammals. Mammals include, among others, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In particular, the individual or participant is a human being. II. Antibodies according to the invention

[0061] Claudin 18.2 (hereinafter also referred to as “CLDN18.2”) is expressed significantly differently in cancerous and normal tissues, which may be due to the fact that the CREB binding site in the promoter region of claudin 18.2 is highly methylated in normal tissues, while the CpG methylation level is reduced during cell carcinogenesis, and CREB is then involved in the activation of claudin 18.2 transcription.

[0062] This document defines the terms "bispecific anti-CD40 and CLDN18.2 antibody," "bispecific antibody that binds specifically to CD40 and CLDN18.2," "bispecific anti-CD40×CLDN18.2 antibody," "CD40 / CLDN18.2 bis antibody," and similar terms as referring to a bispecific antibody capable of binding with sufficient affinity to the target CD40 and claudin 18.2, whereby the bispecific antibody is able to recruit immune cells to the target cells to perform redirected lysis. The bispecific antibody is capable of achieving high-intensity activation of immune cells specifically at the lesion site and low agonistic activity at sites such as hepatocytes that are unable to form a cross-linking effect, in order to achieve specific killing of tumor cells without causing adverse events such as hepatotoxicity.

[0063] In one embodiment, the bispecific anti-CD40×CLDN18.2 antibody of the present invention comprises an amino acid modification, such as an amino acid substitution, addition or deletion, preferably an amino acid substitution, more preferably a conserved amino acid substitution.

[0064] In one embodiment, the amino acid modification described in the present invention occurs in a region outside the CDR (e.g., in the FR). In one embodiment, the substitution is a conservative substitution. A conservative substitution is a substitution of one amino acid by another amino acid within the same class, such as an acidic amino acid by another acidic amino acid, a basic amino acid by another basic amino acid, or a neutral amino acid by another neutral amino acid.

[0065] The table below lists exemplary substitutions: Original Remains Exemplary Substitution Preferred Conservative Amino Acid Substitutions No (A) Val, Leu, Ile Val Arg (R) Lvs, Gln, Asn Lys Asn (N) Gln, His, Asp, Lvs, Arg Gln Rapfen (D) Glu, Asn Glu Cvs (C) Sister, Here Dear Gln (Q) Asn, Glu Asn Glu (E) Asp, Gln Asp Gly (G) No No His (H) Asn, Gln, Lys, Arg Arg Ile (I) Leu, Val, Met, Ala, Phe, Norleucine Leu Leu (L) Norleucine, Ile, Val, Met, Ala, Phe Ile Lys (K) Arg, Gln, Asn Arg Erfullt (M) Leu, Phe, Ile Leu Phe (F) Trp, Leu, Val, Ile, Ala, Tyr Tyr Profit (P) No No Sister (S) Thr Thr Thr (T) Val, Sister Dear Trp (W) Tvr, Phe Tvr Tyr (Y) Trp, Phe, Thr, Ser Phe Val (V) Ile, Leu, Met, Phe, Ala, Norleucine Leu

[0066] In some embodiments, the substitution takes place in the CDR region of the antibody. Typically, the resulting variants exhibit modifications (e.g., improvements) in certain biological properties (e.g., increased affinity) compared to the parent antibody and / or have essentially retained certain biological properties of the parent antibody. Examples of substitution variants are affinity-matured antibodies.

[0067] In certain embodiments, one or more amino acid modifications can be introduced into the Fc region of an antibody offered herein to generate variants of the Fc region. The Fc region variant can comprise a human Fc region sequence (e.g., a human IgGl, IgG2, IgG3, or IgG4 Fc region) that includes an amino acid modification (e.g., a substitution) at one or more amino acid positions.

[0068] It has been shown that the Fc region of the partially agonistic anti-CD40 antibody forms a cross-linking effect with FcγRIIb, which is abundantly expressed on the surface of hepatocytes. This leads to non-specific activation of CD40-expressing immune cells on the surface of hepatocytes, which can cause hepatotoxicity. Therefore, the bispecific anti-CD40×CLDN18.2 antibody of the present invention may also include a modification in the Fc region that reduces the binding affinity of the antibody of the present invention for FcγRIIb in order to reduce or eliminate the cross-linking effect induced by the Fc region. In one embodiment, the modification is located in the CH2 structural domain of the Fc region, e.g., at position 329 (EU number) of the heavy chain (e.g., P329G). In one embodiment, the bispecific anti-CD40×CLDN18.The two antibodies of the present invention feature amino acid substitutions at positions 234 and 235 of the heavy chain (EU numbering). In a particular embodiment, the amino acid substitutions are L234A and L235A (also known as "LALA mutations").

[0069] In one embodiment, a bispecific anti-CD40×CLDN18.2 antibody of the present invention can enhance an immune response without relying on the binding of the antibody to an Fc receptor. For example, the bispecific anti-CD40×CLDN18.2 antibody of the present invention can exhibit an effective CD40 agonist profile without cross-linking with an Fc receptor such as FcγR.

[0070] In one embodiment, a disulfide bond is present between CH1 and CL of the bispecific anti-CD40×CLDN18.2 antibody of the present invention. In another embodiment, the number of disulfide bonds is variable, depending on the shape of the IgG from which the constant structural domain of the antibody is derived, and in some embodiments, two or four disulfide bonds are present between the hinge regions.

[0071] In certain embodiments, it may be necessary to produce a technically modified antibody by cysteine, such as a “thio-MAb”, in which one or more residues of the antibody are replaced by cysteine ​​residues. III. Nucleic acids according to the invention, as well as vectors containing them and host cells

[0072] In one aspect, the present invention provides nucleic acids that encode one of the above-mentioned bispecific antibodies or antigen-binding fragments thereof. The present invention also includes nucleic acids that hybridize with the above-mentioned nucleic acids under stringency conditions, nucleic acids with one or more substitutions (e.g., conserved substitutions), deletions, or insertions compared to the above-mentioned nucleic acids, or nucleic acids with at least 80%, at least 85%, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity of the nucleic acid sequence compared to the above-mentioned nucleic acid.

[0073] In another aspect, the present invention provides vectors containing these nucleic acids. In a preferred embodiment, the vector is an expression vector. It is self-evident to those skilled in the art that vectors commonly used in the field of the present invention can also be applied to the present invention.

[0074] In one embodiment, the present invention provides host cells containing the nucleic acid or the vector.

[0075] The term "host cell" refers to a cell into which an exogenous polynucleotide has been introduced, including the progeny of such a cell. Host cells include "transformants" and "transformed cells," encompassing both primary transformed cells and their derived progeny, regardless of the number of passages. The progeny need not be identical to the parent cells with respect to nucleic acid content but may contain mutations. Progeny of mutants that have been tested or selected for the same function or biological activity in the originally transformed cells are included. Host cells are all types of cell systems that can be used to produce an antibody molecule of the present invention, including eukaryotic cells, e.g., mammalian cells (e.g., CHO cells or HEK293 cells), insect cells, yeast cells, and prokaryotic cells, e.g., E.E. coli cells. Host cells include cultured cells, but also cells in transgenic animals, transgenic plants, or cultured plant or animal tissues. IV. Compositions according to the invention

[0076] In some embodiments, the present invention provides compositions comprising one of the bispecific anti-CD40×CLDN18.2 antibodies or antigen-binding fragments thereof described herein, the composition preferably being a pharmaceutical composition. In one embodiment, the composition further comprises a pharmaceutical excipient. The term "pharmaceutical excipient" refers to a diluent, excipient, carrier, drug carrier, or stabilizer, etc., administered together with the active ingredient.

[0077] In one embodiment, a composition (e.g., a pharmaceutical composition) comprises a bispecific anti-CD40×CLDN18.2 antibody of the invention or an antigen-binding fragment thereof and a combination of one or more other therapeutic agents (e.g., chemotherapeutic agents, cytotoxic agents, vaccines, other antibodies, anti-infective activators, small molecule drugs, or immunomodulators).

[0078] The pharmaceutical compositions of the present invention may also contain one or more other therapeutic agents, wherein these therapeutic agents are required for the respective indication to be treated and cover any substance that is effective in the prevention or treatment of tumors (e.g., cancers) and infections (e.g., chronic infections), and preferably include such therapeutic agents that do not interfere with each other's effects. For example, it is desirable to also provide other therapeutic agents with anti-cancer activity, such as chemotherapeutic agents, cytotoxic agents, vaccines, other antibodies, anti-infective agents, small molecule drugs, or immunomodulators. These therapeutic agents are present in suitable combinations in amounts effective for the intended application. V. Production of the bispecific anti-CD40×CLDN18.2 antibodies according to the invention

[0079] In one embodiment, the present invention provides a method for producing a bispecific anti-CD40×CLDN18.2 antibody, wherein the method involves cultivating the host cells containing a nucleic acid encoding a bispecific anti-CD40×CLDN18.2 antibody or an expression vector comprising the nucleic acid, under conditions suitable for expressing the nucleic acid encoding the bispecific anti-CD40×CLDN18.2 antibody, and optionally isolating the bispecific anti-CD40×CLDN18.2 antibody. In one embodiment, the method further comprises obtaining a bispecific anti-CD40×CLDN18.2 antibody from the host cell (or the host cell culture medium).

[0080] For the recombination and production of the bispecific anti-CD40×CLDN18.2 antibody according to the invention, nucleic acids encoding the bispecific anti-CD40×CLDN18.2 antibody are first isolated, and these nucleic acids are inserted into vectors for further cloning and / or expression in host cells. Such nucleic acids can be easily isolated and sequenced using conventional protocols, for example, using oligonucleotide probes capable of binding specifically to nucleic acids encoding the bispecific anti-CD40×CLDN18.2 antibody of the present invention.

[0081] The bispecific anti-CD40×CLDN18.2 antibodies of the present invention, prepared as described herein, can be purified according to the prior art, e.g., by high-performance liquid chromatography, ion-exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like. The actual conditions for the purification of a particular protein also depend on factors such as net charge, hydrophobicity, hydrophilicity, etc., which are known to those skilled in the art. The purity of the bispecific anti-CD40×CLDN18.2 antibody of the present invention can be determined by one of the various known analytical methods, including size exclusion chromatography, gel electrophoresis, high-performance liquid chromatography, and the like. VI. Combination products or kits

[0082] In some embodiments, the present invention also provides combination products comprising a bispecific anti-CD40×CLDN18.2 antibody or an antigen-binding fragment of the present invention or an immunoconjugation thereof and one or more other therapeutic agents (e.g. chemotherapeutic agents, other antibodies, cytotoxic agents, anti-infective activators, small molecule drugs or immunomodulators, etc.).

[0083] In some embodiments, the combination product is used to prevent or treat a tumor. In some embodiments, the tumor is cancer or the like.

[0084] In some embodiments, two or more of the components of the combination product can be administered to a participant sequentially, separately, or in combination at the same time.

[0085] In some embodiments, the present invention also provides kits comprising a bispecific anti-CD40×CLDN18.2 antibody, a pharmaceutical composition, an immunoconjugate or a combination product of the present invention, and optionally a package insert for administration instructions.

[0086] In some embodiments, the present invention also provides a pharmaceutical article comprising a bispecific anti-CD40×CLDN18.2 antibody, a pharmaceutical composition, an immunoconjugate or a combination product of the present invention, wherein the pharmaceutical article optionally includes a package leaflet for instructions on administration. VII. Uses and therapeutic methods of the bispecific anti-CD40×CLDN18.2 antibody of the present invention

[0087] In one aspect, the present invention relates to a method for modulating an immune response in an individual. The method comprises administering an effective amount of a bispecific anti-CD40×CLDN18.2 antibody, or a pharmaceutical composition, or an immunoconjugate, or a combination product comprising the bispecific anti-CD40×CLDN18.2 antibody, to subjects, thereby improving the previously weak antibody-dependent cell-mediated cytotoxicity (ADCC) of the monoclonal CLDN18.2 antibody by activating B cells and downstream immune-responding cells, such as T cells, to enhance the killing effect through the anchoring of a CD40 antibody, which activates B cells, to CLDN18.2-expressing cells. The mechanism of action consists in the bispecific anti-CD40×CLDN18.2-antibody induces a cross-linking effect, leading to a significant immune activation response when a cross-linking effect is formed, and to no or a weak immune activation response when no cross-linking effect is present.

[0088] In one embodiment, a therapeutically effective amount of a therapeutically effective bispecific anti-CD40×CLDN18.2 antibody or pharmaceutical composition or immunoconjugate or combination product disclosed herein restores, enhances, stimulates or increases the immune response in the subject.

[0089] In one embodiment, a bispecific anti-CD40×CLDN18.2 antibody disclosed herein has a significantly higher agonistic activity when it binds to CLDN18.2 on the cell surface than when it does not bind to the cell surface, and is able to reduce the non-specific agonistic activity to the greatest extent and increase the therapeutic index.

[0090] In one embodiment, the bispecific anti-CD40×CLDN18.2 antibody disclosed herein, which has been modified with Fc fragments, does not bind to Fc receptors in the liver; furthermore, the bispecific antibody of the present invention has an activation effect that depends on the CLDN18.2 target, which is a tumor-specific target, and therefore the bispecific anti-CD40×CLDN18.2 antibody of the present invention can completely avoid hepatotoxicity.

[0091] In another aspect, the present invention relates to a method for preventing or treating a tumor (e.g., cancer) in a subject, wherein the method comprises administering an effective amount of a bispecific anti-CD40×CLDN18.2 antibody, as disclosed herein, or of a pharmaceutical composition, immunoconjugate, or combination product containing it, to the participant.

[0092] In some embodiments, the tumor is a cancer that abnormally expresses CLDN 18.2. In some embodiments, the cancer that expresses CLDN 18.2. abnormally expressed, for example, bone cancer, blood cancer, lung cancer, liver cancer, pancreatic cancer, esophageal cancer, skin cancer, head and neck cancer, melanoma of the skin or eye, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, prostate cancer, uterine cancer, cancer of the sexual and reproductive organs, Hodgkin's lymphoma, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, bladder cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, tumors of the central nervous system (CNS), neuroectodermal tumors, tumors of the spinal axis, gliomas, spinal meningiomas and pituitary adenomas, and preferably the cancers are stomach cancer, Pancreatic cancer, esophageal cancer, ovarian cancer, or lung cancer.

[0093] In some embodiments, the tumor is a cancer that abnormally expresses CD40. In some embodiments, the cancer includes, but is not limited to, solid tumors, hematological cancers, soft tissue tumors, and metastatic lesions. Examples of solid tumors are malignant tumors such as sarcomas and carcinomas (including adenocarcinomas and squamous cell carcinomas) of various organ systems, e.g., those that invade the liver, lungs, breast, lymphatic system, gastrointestinal tract (e.g., colon), pancreas, urogenital tract (e.g., kidneys, bladder epithelial cells), prostate, and pharynx. Adenocarcinomas include malignant tumors such as most cancers of the colon, rectal cancer, renal cell carcinoma, liver cancer, non-small cell lung cancer, small bowel cancer, and esophageal cancer.Squamous cell carcinomas include malignant tumors such as carcinomas of the lung, esophagus, skin, head and neck region, oral cavity, anus, and cervix. In one embodiment, the cancer is a melanoma, e.g., an advanced melanoma. In another embodiment, the cancer is a lymphoma, renal cell carcinoma, non-small cell lung carcinoma, liver cancer, pancreatic cancer, colorectal adenocarcinoma, or breast cancer. Metastatic lesions of the aforementioned cancers can also be treated or prevented using the methods and compositions of the present invention.

[0094] Non-restrictive examples of cancers that should be treated preferentially include lymphomas (e.g., diffuse large B-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma), breast cancer (e.g., metastatic breast cancer), hepatocellular carcinoma (HCC), lung cancer (e.g., non-small cell lung cancer (NSCLC), such as stage IV or recurrent non-small cell lung cancer, or NSCLC adenocarcinoma or NSCLC squamous cell carcinoma), myeloma (e.g., multiple myeloma), leukemia (e.g., chronic myeloid leukemia), skin cancer (e.g., melanoma (e.g., stage III or IV melanoma) or Merkel cell carcinoma), head and neck cancer (e.g., head and neck squamous cell carcinoma (HNSCC)), spinal cord dysplasia syndrome, and bladder cancer. (e.g. wandering cell carcinoma), kidney cancer (e.g. renal cell carcinoma, e.g. clear cell renal cell carcinoma, e.g. advanced or metastatic clear cell renal cell carcinoma) and colon cancer.Furthermore, refractory or recurrent malignant diseases (e.g., pancreatic cancer) can be treated with the anti-CD40 antibodies described here, or pharmaceutical compositions or immunoconjugates or combination products containing them.

[0095] The participant may be a mammal, e.g., a primate, preferably an advanced primate, e.g., a human (e.g., a patient suffering from or at risk of developing a disease described herein). In one embodiment, the participant suffers from or is at risk of developing a disease described herein (e.g., a tumor described herein). In some embodiments, the participant is receiving or has received other treatments, e.g., chemotherapy and / or radiation therapy. Alternatively or in combination, the participant is immunocompromised due to infection or is at risk of becoming immunocompromised due to infection.

[0096] In some embodiments, the methods described herein for prevention or treatment further include the combined administration of a bispecific anti-CD40×CLDN18.2 antibody or pharmaceutical composition or immunoconjugate or combination product disclosed herein and one or more other therapies, e.g. therapeutic procedure and / or other therapeutic agents, to the participant or individual.

[0097] The bispecific anti-CD40×CLDN18.2 antibodies of the present invention (and the pharmaceutical compositions or immunoconjugates containing them) can be administered by any suitable method, including parenteral, intrapulmonary, and intranasal administration, and, if required for localized treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intra-arterial, intraperitoneal, or subcutaneous administration. Depending on whether short-term or long-term administration is required, the drug can be administered by any suitable route, e.g., by injection, such as intravenous or subcutaneous injection. Various dosing regimens are discussed here, including, but not limited to, single administration or multiple administrations at different time points, push administration, and pulsed infusion.

[0098] For the prevention or treatment of a disease, the appropriate dose of the bispecific anti-CD40×CLDN18.2 antibody of the present invention (when administered alone or in combination with one or more other therapeutic agents) depends on the type of disease to be treated, the type of bispecific anti-CD40×CLDN18.2 antibody, the severity and course of the disease, whether the bispecific anti-CD40×CLDN18.2 antibody is administered for prophylactic or therapeutic purposes, previous treatments, the patient's clinical history and response to the bispecific anti-CD40×CLDN18.2 antibody, and the judgment of the treating physician. The bispecific anti-CD40×CLDN18.2 antibody is administered to the patient appropriately as a single treatment or over a series of treatments. The dosage of the bispecific anti-CD40×CLDN18.2 antibody and the treatment regimen can be determined by a specialist.

[0099] It becomes clear that it is possible to replace the bispecific anti-CD40×CLDN18.2 antibody with an immunoconjugate or a composition or combination product of the present invention for one of the above-mentioned prophylaxis or treatments.

[0100] The following exemplary embodiments are described to facilitate understanding of the present invention. This is not intended, and should not be interpreted in any way, to limit the scope of protection of the invention. Example of implementation

[0101] Unless otherwise stated, the experimental methods used in the following embodiments are those of conventional chemistry, biochemistry, organic chemistry, molecular biology, microbiology, recombinant DNA technology, genetics, immunology and cell biology within the scope of the technology in this field. Unless otherwise stated, the materials, reagents and the like used in the following embodiments are commercially available. Example 1: Production of a bispecific anti-CD40×CLDN18.2 antibody

[0102] The anti-CD40 antibodies C8-WT, C8-2, C8-6, C8-10 of patent application CN202110577432.9 were developed as bispecific antibodies of the in Figs. The structure shown in 1 was constructed using the VHH of the anti-CLDN18.2 antibody NA3SH1-T4-hVH6 of patent application CN202110795793.0, with the individual antibody sequences shown in Tables 1a-1d. Table 1a: CDR sequences in the variable region of the anti-CD40 antibody light chain (defined by AbM numbering) Antibody Name SEQ ID NO: LCDR1 SEQ ID NO: LCDR2 SEQ ID NO: LCDR3 C8-WT 1 RSSQGIRSSLA 2 GAS LIGHT 3 QQLNSFPST C8-2 1 RSSQGIRSSLA 2 GAS LIGHT 3 QQLNSFPST C8-6 1 RSSQGIRSSLA 2 GAS LIGHT 3 QQLNSFPST C8-10 1 RSSQGIRSSLA 2 GAS LIGHT 3 QQLNSFPST Table 1b: CDR sequences in the variable region of the heavy chain of the anti-CD40 antibody (defined by AbM numbering) Antibody Name SEQ ID NO: HCDR1 SEQ ID NO: HCDR2 SEQ ID NO: HCDR3 C8-WT 4 GFTFGSEMN 5 YISSSGETTD 6 DVFFFDSSGDNGAYGMDV C8-2 4 GFTFGSEMN 5 YISSSGETTD 7 DVFFFSPSSGDNGAYGMDV C8-6 4 GFTFGSEMN 5 YISSSGETTD 8 DVFFFDSSGSPGAYGMDV C8-10 4 GFTFGSEMN 5 YISSSGETTD 9 DVFFFDSSGFPGAYGMDV Table 1c: Sequence of the variable region of the heavy chain and the variable region of the light chain of the anti-CD40 antibody Antibody Name the variable region of the light chain the variable region of the heavy chain C8-WT DIQLTQSPSSLTASVGDRVTITCRSSQGIR SSLAWYQQKPGKPPKLLIYGASSLEGGV PSRFSGSGSGTDFTLTISSLQPEDFATYYC QQLNSFPSTFGQGTKLEIK (SEQ ID NO:10) EVQLLESGGGLVRPGGSLRLSCAASGFTF GSYEMNWVRQAPGKGLEWVSYISSSGET TDYADSVKGRFTVSRDNSKNLLYLQMN SLRAEDTAVYYCARDVFFFDSSGDNGAY GMDVWGQGTMVTVSS (SEQ ID NO:11) C8-2 SEQ ID NO:10 EVQLLESGGGLVRPGGSLRLSCAASGFTF GSYEMNWVRQAPGKGLEWVSYISSSGET TDYADSVKGRFTVSRDNSKNLLYLQMN SLRAEDTAVYYCARDVFFFSPSGDNGAY GMDVWGQGTMVTVSS (SEQ ID NO:12) C8-6 SEQ ID NO:10 EVQLLESGGGLVRPGGSLRLSCAASGFTF GSYEMNWVRQAPGKGLEWVSYISSSGET TDYADSVKGRFTVSRDNSKNLLYLQMN SLRAEDTAVYYCARDVFFFDSSGSPGAY GMDVWGQGTMVTVSS (SEQ ID NO:13) C8-10 SEQ ID NO:10 EVQLLESGGGLVRPGGSLRLSCAASGFTF GSYEMNWVRQAPGKGLEWVSYISSSGET TDYADSVKGRFTVSRDNSKNLLYLQMN SLRAEDTAVYYCARDVFFFDSSGFPGAY GMDVWGQGTMVTVSS (SEQ ID NO:14) Table 1d: Sequence of anti-CLDN18.2 nanoantibodies CDR sequence (defined by AbM numbering) CDR1 CDR2 CDR3 GSIFHIPVMG (SEQ ID NO:15) GISRGGTTN (SEQ ID NO:16) LVVSGIGSTLEV (SEQ ID NO:17) Nano-antibody sequence QVQLVESGGGLVQPGGSLRLSCAASGSIFHIPVMGWYRQAPGKGLELVAGISRGGTTNYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYCNVLVVSGIGSTLEVWGQGTLVTVSS (SEQ ID NO. 18)

[0103] In particular, the obtained nucleotide sequences encoding the variable regions of the heavy chain of the four anti-CD40 antibodies described above, and the nucleotide sequences encoding the variable regions of the light chain of the anti-CD40 antibodies, were spliced ​​with the nucleotide sequences encoding fragments of the constant regions of the heavy and light chains to obtain the corresponding full-length heavy and light chain nucleotide sequences encoding the anti-CD40 antibodies. To reduce the binding of the antibody according to the invention to the Fc receptor on hepatocytes, the Fc of the bispecific antibody was used in the hIgG1 (N297Q) Fc isoform. The nucleotide sequence encoding the VHH of the anti-CLDN18 described above...The 2-antibody encoded was then attached to the C-terminus of the constant region of the heavy chain of each of the four different anti-CD40 antibodies by means of a linkage sequence, thereby creating the heavy chain sequence of the bispecific antibody, as in . Fig.Figure 1 shows the following, where the linkage sequence encodes a flexible adapter commonly used in the technique for linking different peptide molecules, for example, the adapter shown as GGGGSGGGGGGGGS (SEQ ID NO:25). The resulting coding nucleotide sequences were then constructed onto the eukaryotic expression vector plasmid pcDNA3.4, and the heavy and light chains of the bispecific antibodies were co-expressed in CHO-K cells using the ExpiCHO Transient Expression System (Thermo Fisher, A29133) according to the manufacturer's instructions, and then affinity purification was performed by COLUMN XK16 / 20 (acquired from Cytiva). The bispecific anti-CD40×CLDN18.2 antibodies C8-WT-NA3S-HC, C8-2-NA3S-HC, C8-6-NA3S-HC and C8-10-NA3S-HC, respectively, which have the amino acid sequence of the heavy and light chain numbered in Table 2, were each obtained. Table 2: Amino acid sequence of the bispecific antibody anti-CD40×CLDN18.2 Antibody Name lightweight chain heavy chain C8-WT-NA3S-HC SEQ ID NO:23 SEQ ID NO:19 C8-2-NA3S-HC SEQ ID NO:23 SEQ ID NO:20 C8-6-NA3S-HC SEQ ID NO:23 SEQ ID NO: 21 C8-10-NA3S-HC SEQ ID NO:23 SEQ ID NO:22 Example 2: Analysis of the affinity activity of the bispecific anti-CD40×CLDN18.2 antibody 2.1 Binding ability of bispecific antibodies to the CD40 protein

[0104] The four obtained bispecific antibodies were tested for their affinity for the extracellular structural domain of human CD40 (Uniprot: positions 21-193 of P25942) using ELISA. This extracellular structural domain of human CD40 carries a His tag and is also referred to here as the P17-His fusion protein.

[0105] 2 µg / ml of the P17-His fusion protein were encapsulated in 30 µl per well in a 96-well ELISA plate and incubated overnight at 4 °C. The following day, 5% PBSM (PBS + 5% milk) was blocked at room temperature for 2 h, and then the bispecific anti-CD40×CDN18.2 antibody was added in a gradient dilution (20 nM in the first well, 10-fold dilution in the second, 3-fold dilution in the third to seventh wells, and 4-fold dilution in the seventh to eighth wells), with positive control APX005 (sequence from Apexigen Inc. US20120301488A1, manufactured in-house) or isotype IgG1 negative control. After 1 hour incubation at room temperature, the sample was washed three times with PBST (PBS+0.05% Tween-20), then 30 µ1 Goat-anti-human-Fc-HRP (abcam, ab97225) was added.After incubation for one hour at room temperature and subsequent washing three times with PBST (PBS + 0.05% Tween-20), the stain was developed by adding TMB chromogen solution for 5–30 minutes. Upon completion, the OD450 was measured using an enzyme marker (Beckman Coulter), and the results were analyzed and graphically displayed using Graphpad 7.0 to assess the binding of bispecific antibodies to the P17-His fusion protein.

[0106] The results are in Fig. 2 shown. As in Fig. As can be seen in Figure 2, the positive control APX005 bound the P17-His fusion protein with an EC10. 50 -value of 0.06124 nM, and the bispecific antibodies C8-WT-NA3S-HC, C8-2-NA3S-HC, C8-6-NA3S-HC and C8-10-NA3S-HC bound the P17-His fusion protein with EC 50 -values ​​of 0.1098 nM, 0.1270 nM, 0.1015 nM and 0.1044 nM, thus showing a comparable affinity to the positive control APX005. 2.2 Binding ability of bispecific antibodies to CD40 expressed on the cell surface

[0107] To test the binding affinity of bispecific antibodies to surface-expressed CD40, CHO-K cells expressing human CD40 (Uniprot: P25942) on the cell surface (Thermo Fisher) were generated. Specifically, CHO-K cells expressing human CD40 on the cell surface (hereinafter also referred to as huCD40-CHO-K cells) were obtained by cloning the human CD40 encoding sequence into the polyclonal site of a pcDNA3.4 vector (Invitrogen) and subsequently introducing the expression vector expressing human CD40 into CHO-K cells for eukaryotic expression.

[0108] The huCD40-CHO-K cells were placed in a plate with 96 wells of 1.0×10 5Cells / wells were inoculated and a gradient dilution (115.6 nM in the first well, 10-fold dilution in the second, 3-fold gradient dilution in the third to seventh wells, and 4-fold dilution in the seventh to eighth wells) of a bispecific anti-CD40×CDLN18.2 antibody was added, with APX005 as the positive control and isotypic IgG1 as the negative control. After a 30-minute incubation at 4 °C, the cells were washed and 100 µl of a 1:300 dilution of Goat F(ab')2 Anti-human Fc(PE) was added.

[0109] (Abcam, ab98596) was added and incubated for 30 minutes. Subsequently, the cells were washed and the binding of the bispecific antibody of the present invention to the CD40 expressed on the cell surface was detected by flow cytometry (Beckman Coulter).

[0110] The test results are in Fig. 3 shown. Fig.Figure 3 shows that different concentrations of the bispecific anti-CD40×CLDN18.2 antibody exhibit the ability to bind to huCD40-CHO-K cells, and the binding ability showed a concentration dependence in the concentration range of the bispecific antibody from 0.015 nM to 115.6 nM. 2.3 Affinity of bispecific antibodies for CLDN18.2 expressed on the cell surface

[0111] To test the affinity of a bispecific antibody for surface-expressed CLDN18.2, HEK293 cells expressing human CLDN18.2 on the cell surface were generated. Specifically, a full-length DNA sequence of human CLDN18.2 (see SEQ ID NO:15 of WO2020238730A1 for the amino acid sequence) was constructed on the pLVX puro plasmid (Clontech, Cat# 632164). The resulting plasmid was then transformed into HEK293 cells (ATCC®CRL-1573™) by electrotransformation. The HEK293 cell line, which overexpresses human CLDN18.2 and is also referred to here as “18.2-HEK293 cells”, was obtained by stress screening for puromycin resistance and identification of the clone using the antibody IMAB362 (Ganymed, Germany, an antibody that specifically binds to CLDN18.2).

[0112] The 18.2-HEK293 cells were placed in a plate with 96 wells measuring 1.0×10 5Cells / wells were inoculated and a gradient dilution (115.6 nM in the first well, 10-fold dilution in the second, 3-fold gradient dilution in the third to seventh wells, and 4-fold dilution in the seventh to eighth wells) of a bispecific antibody of the present invention, a positive control NA3SH1-T4-hVH6 (amino acid sequence as in SEQ ID NO. 24), or the isotype IgG1 negative control was added. After a 30-minute incubation at 4 °C, the cells were washed and incubated for 30 minutes with 100 µl of a 1:300 dilution of Goat F(ab') 2 Anti-human Fc (PE). Subsequently, the cells were washed and the binding of the bispecific antibody to CLDN18.2, which is expressed on the surface of HEK293 cells, was detected by flow cytometry.

[0113] Fig.Figure 4 shows that different concentrations of the bispecific anti-CD40×CLDN18.2 antibody bind to 18.2-HEK293 cells, and the binding affinity showed a dependence on the concentration of the bispecific antibody over a concentration range of the bispecific antibody from 0.015 nM to 115.6 nM. 2.4 Binding ability of bispecific antibodies to CLDN18.1 expressed on the cell surface

[0114] To test the affinity of a bispecific antibody for CLDN18.1 expressed on the cell surface, HEK293 cells were generated expressing human CLDN18.1 (see SEQ ID NO:16 of WO2020238730A1 for the amino acid sequence) on the cell surface (see above for the method of production, hereinafter also referred to as “18.1-HEK293 cells”).

[0115] 18.1-HEK293 cells were placed in a plate with 96 wells measuring 1.0×10 5Cells / wells were inoculated and a gradient dilution (115.6 nM in the first well, 10-fold dilution in the second, 3-fold gradient dilution in the third to seventh wells, and 4-fold dilution in the seventh to eighth wells) of a bispecific antibody of the present invention or of a positive antibody, NA3SH1-T4-hVH6, was added. The cells were washed and 100 µl of a 1:300 dilution of PE-labeled Goat F(ab')2 anti-human Fc (PE) was added and incubated for 30 minutes at 4 °C. Subsequently, the cells were washed and the binding of the bispecific antibody to the CLDN18.1 molecule expressed on the surface of HEK293 cells was detected by flow cytometry.

[0116] The results showed that different concentrations of the bispecific anti-CD40×CLDN18.2 antibodies do not bind to 18.1-HEK293 cells, suggesting that the bispecific antibodies obtained by the present invention bind specifically to CLDN18.2. Example 3: In vitro functional testing of the bispecific antibody Anti-CD40×CLDN18.2

[0117] To test whether the bispecific antibody of the present invention is able to activate the NF-xB signaling pathway downstream of CD40 under different circumstances, in this example a CD40-NF-κB Jurkat-Luciferase reporter gene cell line stably expressing CD40 (Uniprot No. P25942) was used. 3.1 Construction of the CD40-NF-ĸB-Jurkat-Luciferase reporter gene cell line

[0118] The pGL4.30 plasmid (promega, #E8481), containing the NF-AT-re nucleic acid sequence, was first transfected into Jurkat cells (ATCC®TIB-152™) using an electrotransfer machine (Invitrogen, Neon™ Transfection System, MP922947). The resulting cells were then transferred by volume and antibiotic-free to RPMI 1640 medium (Hyclone, SH30243.01) with 10% FBS (Gibco, 15140-141), inoculated into 6-well cell culture dishes, and cultured for 48 hours. The cells were then distributed into a plate with 96 wells at an average density of 1500 cells / well, and Thiamphenicol B (Genpei, S160J7) at a final concentration of 500 µg / ml was added for screening. The growth of the cell line clones was observed for approximately 2-3 weeks, and the cell lines that had formed clones were selected and transferred to a plate with 24 wells. When the cells had enlarged after culture,Some of the clones were taken and transferred to a 96-well, white-bottomed plate (Corning, 3610). The cells were then stimulated with phorbol ester (at a concentration of 10 ng / mL) and ionomycin (at a concentration of 1 nM) and incubated for 6 hours at 37°C in a 5% CO2 incubator. Bright-Lite substrate (Vazyme, DD1204-03) was then added, and the expression levels of various NF-κB clones were evaluated by reading the signal value in an enzyme counter (Molecular Devices: Spectramax i3x). This resulted in the Jurkat cell line (referred to as NF-κB Jurkat cells) with high expression of the NF-κB gene.

[0119] Based on this, the full-length expression gene sequence of human CD40 (Uniprot No. P25942) was stably transfected into the aforementioned NF-κB Jurkat cells to screen the monoclonal cell line. The recombinant CD40L protein (ACRO Biosystems, No. CDL-H5248) was added to the culture system of this cell line to activate the transcription and expression of the intracellular NF-κB luciferase reporter gene via the CD40-CD40L signaling axis, and the fluorescence signals generated by the addition of the luciferase catalytic substrate were used to detect and generate the corresponding CD40-expressing cell line, which is designated as the CD40-NF-κB Jurkat luciferase reporter cell line. 3.2 Activation of the NF-κB signaling pathway by bispecific antibodies in the presence of crosslinking agents

[0120] In this section, the ability of a bispecific antibody obtained by the present invention to activate the downstream NF-xB signaling pathway by binding to CD40 was investigated in the presence of a crosslinking agent, wherein the expression of a luciferase reporter gene indicated the activation of the NF-κB signaling pathway.

[0121] Specific embodiments are as follows: A gradient dilution (28.9 nM in the first well, 5-fold gradient dilution) of the bispecific antibody, the positive control APX005, or the isotype IgG1 negative control was mixed with a final concentration of 5 µg / ml of the crosslinking agent (AffiniPure F(ab')2 Fragment Goat Anti-Human IgG, Fcγ fragment-specific, Jackson Immunoresearch, Article No. 109-006-098) and incubated for 30 min in a 96-well cell culture plate, then CD40 NF-κB Jurkat cells were inoculated in a quantity of 1.0 × 10 5Cells were placed in the cell culture plates and incubated for 6 hours at 37°C. Finally, 30 µl of the luciferase substrate Bright-Lite (Vazyme, DD1204-03) was added to each well, and the fluorescence value of the 96-well plate was determined after shaking for 2 minutes.

[0122] The results are in Fig. Figure 5A shows that in the presence of the crosslinking agent, both bispecific anti-CD40×CLDN18.2 antibodies underwent the corresponding crosslinking reaction, which can activate the NF-κB signaling pathway downstream of CD40 and generate fluorescence. 3.3 Bispecific antibodies do not activate the NF-xB signaling pathway in the absence of crosslinking agents

[0123] In this section, the ability of a bispecific antibody obtained by the present invention to activate the downstream NF-xB signaling pathway by binding to CD40 was investigated in the absence of a crosslinking agent, wherein the expression of a luciferase reporter gene indicated the activation of the NF-κB signaling pathway.

[0124] Specific embodiments are essentially the same as those in section 3.2, except that no crosslinking agent is added.

[0125] As in Fig.As shown in Figure 5B, the positive control APX005 activated the NF-κB signaling pathway downstream of CD40 in the absence of a crosslinking agent, whereas the bispecific antibodies of the present invention did not activate the NF-κB signaling pathway to a significant extent, or only to a lesser degree, and certain bispecific antibodies even functioned comparably to the negative control. It is evident that, in the absence of a crosslinking agent, the bispecific antibody of the present invention is a weakly agonistic antibody. Due to the weak activation capacity of the bispecific antibodies, it can be assumed that the bispecific antibodies of the present invention weakly agonize the CD40 molecule while simultaneously exhibiting fewer toxic side effects than the control antibodies.

[0126] In the presence or absence of cross-linking effects, the bispecific antibodies of the present invention exhibit a significant difference in agonistic activity, which very effectively contributes to reducing non-specific agonistic activity and increasing the therapeutic index. 3.4 In the presence of 18.2-HEK293 cells, the bispecific antibodies activated the NF-xB signaling pathway.

[0127] In this section, the ability of a bispecific antibody obtained by the present invention to activate the downstream NF-xB signaling pathway by binding to CD40 was investigated in the presence of 18.2-HEK293 cells, wherein the expression of a luciferase reporter gene indicated the activation of the NF-κB signaling pathway.

[0128] Specific embodiments are as follows: CD40-NF-κB-Jurkat cells were cultured in cell culture plates with 1.0×10 5Cells / depression were placed, then 18.2-HEK293 cells with 1.0×10 were added. 5 Cells / wells were added, and a gradient dilution (5.8 nM in the first well, 10-fold dilution in the second well, 2-fold gradient dilution in the third to seventh wells, and 4-fold dilution in the seventh to eighth wells) of the respective bispecific antibody or the isotype IgG1 negative control was added to the spread cells and incubated for 6 hours at 37 °C. Finally, 30 µl of the luciferase substrate Bright-Lite (Vazyme, DD1204-03) was added to each well, and the fluorescence value of the 96-well plate was determined after shaking for 2 minutes.

[0129] As in Fig.As shown in Figure 6A, each of the bispecific antibodies of the present invention underwent a cross-linking effect in the presence of 18.2-HEK293 cells, which significantly activated the NF-κB signaling pathway downstream of CD40, and this activation capability showed a concentration-dependent effect over a concentration range of the bispecific antibodies of about 0.0045 nM to 5.8 nM. 3.5 Bispecific antibodies do not activate the NF-xB signaling pathway in the presence of negative cells that do not express CLDN18.2.

[0130] In this section, the ability of a bispecific antibody obtained by the present invention to activate the downstream NF-xB signaling pathway by binding to CD40 was investigated in the presence of HEK293 cells that do not express CLDN18.2.

[0131] Specific embodiments are as follows: CD40-NF-κB-Jurkat cells were cultured in cell culture plates with 1.0×10 5Cells / well were placed, then HEK293 cells (ATCC®CRL-1573™) with 1.0×10 5 Cells / wells were added, and a dilution (5.8 nM in the first well, 10-fold dilution in the second well, 2-fold gradient dilution in the third to seventh wells, and 4-fold dilution in the seventh to eighth wells) of the respective bispecific antibody or the isotype IgG1 negative control was added to the spread cells and incubated for 6 hours at 37 °C. Finally, 30 µl of the luciferase substrate Bright-Lite (Vazyme, DD1204-03) was added to each well, and the fluorescence value of the 96-well plate was determined after shaking for 2 minutes.

[0132] As in Fig. As shown in Figure 6B, none of the bispecific antibodies of the present invention activated the NF-xB signaling pathway downstream of CD40 in the absence of HEK293 expressing CLDN18.2.

[0133] The results of Fig. 6A and Fig. Figure 6B shows that the ability of the bispecific antibodies of the present invention to activate the NF-κB signaling pathway downstream of CD40 depends on the presence of CLDN18.2 in a concentration-dependent manner. This suggests that the bispecific antibody of the present invention can effectively activate the NF-κB signaling pathway downstream of CD40 in CD40-NF-κB Jurkat cells by binding to CLDN18.2 on 18.2-HEK293 cells to create a "crosslinking effect" and then promoting the immune response of APC cells and downstream T cells to achieve a tumor-killing effect. Furthermore, by appropriate modification of the Fc region of the bispecific antibody, the non-specific binding of the antibody to hepatocytes is effectively avoided, and the hepatotoxic side effects of the antibody are avoided or reduced. Example 4 Functional test of the bispecific anti-CD40×CLDN18.2 antibody in an animal model

[0134] In this example, the tumor-inhibiting ability and hepatotoxicity of the bispecific antibody of the present invention were tested in an animal model. In this example, MC-38 cells (Mouse Colon Cancer Cells, Nammo Biologics, Catalogue No. NM-S13-TM10) overexpressing CLDN18.2, hereinafter referred to as huCLDN18.2-MC38 cells (see the construction method in Example 2.3 of the present application), were used as tumor cells, and the test animals were 6-8 week old (20-22 g) female humanized CD40 mice C57BL / 6-Cd40. tm1(CD40) / Bcgen (Bioceto, article no.: 110009). The experimental mice were kept in a separate, ventilated box at constant temperature and humidity, with a rearing temperature of 21-24°C and a humidity of 30-53%. Resuspensed huCLDN18.2-MC38 cells were used in a quantity of 2×10 6 Cells per mouse were injected subcutaneously into the right side of the back (day 0), and the subcutaneously loaded tumor volume of the mice was approximately 100-130 mm³. 3Upon reaching day 7, mice with large differences in tumor volume were excluded from the samples, and then the mice were randomly grouped according to tumor volume (5 mice in each group): the PBS-treated group, the CCl4-treated group (positive control for chemical hepatotoxicity), and the PBS-treated group; the group receiving the monoclonal antibody selicrelumab (Abgenix, Phase I clinical trial, heavy chain and light chain amino acid sequences as shown in SEQ ID NO:26 and SEQ ID NO:27, respectively); the group receiving the monoclonal antibody C8-WT (heavy chain and light chain amino acid sequences as shown in SEQ ID NO:28 and SEQ ID NO:23, respectively); and the bispecific antibodies C8-WT-NA3S-HC and C8-2-NA3S-HC, with two dose groups of 1 mpk and 20 mpk, respectively, for each antibody administration group. The medication was administered intravenously (IV) twice weekly for a total of 3 weeks.) administered. 4.1 Demonstration of the tumor-inhibiting ability of bispecific antibodies

[0135] Tumor length (mm) and width (mm) were observed and recorded at each time point, and tumor volume (V) was calculated as V = (length × width) 2 ) / 2, and the tumor inhibition rate TGI (%) = (1 - mean tumor volume of the administered group / mean tumor volume of the PBS-treated group) × 100%. The tumor inhibition results are in Fig. Figure 7 and Tables 3-4 illustrate this. The results of the complete remission rate analysis in Table 3 show that the bispecific antibodies C8-WT-NA3S-HC and C8-2-NA3S-HC achieved complete tumor remission (tumor volume less than 5 mm²) on day 18 at both high and low doses. 3) showed, while the monoclonal control antibody selicrelumab only showed complete tumor remission on day 21; the bispecific antibodies C8-WT-NA3S-HC and C8-2-NA3S-HC showed complete tumor remission in all mice at the high dose on day 25, while the monoclonal control antibody selicrelumab showed complete remission in only 3 mice at the high dose on day 25; the monoclonal control antibody selicrelumab and the bispecific antibody C8-WT-NA3S-HC showed the death of 2 mice at the low dose, while the bispecific antibody C8-2-NA3S-HC showed no deaths at either the high or low dose. From the results of tumor inhibition in Fig.Figure 7 and Table 4 show that the two bispecific antibodies C8-WT-NA3S-HC and C8-2-NA3S-HC produced excellent tumor inhibition in mice, with the bispecific antibody C8-2-NA3S-HC significantly outperforming the monoclonal control antibody selicrelumab at low doses; the bispecific antibody showed better tumor-inhibiting activity compared to the monoclonal parent antibody C8-WT, suggesting that the bispecific antibody specifically kills CLDN18.2-positive tumor cells in vivo by cross-linking. Table 3: Number of complete remissions in mice with bispecific antibodies in vivo Groups Number of complete remissions / total number D14 D18 D21 D25 D27 Selicrelumab 1mpk 0 / 5 0 / 5 1 / 3 1 / 3 1 / 3 20mpk 0 / 5 0 / 5 0 / 5 3 / 5 5 / 5 C8-WT 1mpk 0 / 5 0 / 5 0 / 5 0 / 5 0 / 3 20mpk 0 / 5 0 / 5 0 / 5 0 / 4 0 / 4 C8-WT-NA3S-HC 1mpk 0 / 5 1 / 5 1 / 5 1 / 3 1 / 3 20mpk 0 / 5 2 / 5 4 / 5 5 / 5 5 / 5 C8-2-NA3S-HC 1mpk 0 / 5 1 / 5 1 / 5 1 / 5 2 / 5 20mpk 0 / 5 1 / 5 3 / 5 5 / 5 5 / 5 Table 4: Tumor inhibition rate in mice with bispecific antibodies in vivo Tumor inhibition rate (%) = (1 - mean tumor volume of the experimental group / mean tumor volume of the control group) × 100% Expert day PBS Selicrelumab 1 mpk Selicrelumab 20 mpk C8-WT 1 mpk C8-WT 20 mpk C8-WT-N A3S-HC 1 mpk C8-WT-N A3S-HC 20 mpk C8-2-NA 3S-HC 1 mpk C8-2-NA 3S-HC 20 mpk 11 0.0 27,93 11,65 25,07 24,00 -4,26 41,06 19,85 -9,43 14 0.0 40,39 34,62 26,81 19,44 -10,75 49,59 19,51 2,57 18 0.0 68,33 88,10 54,73 51,37 48,22 87,80 83,34 83,98 21 0.0 77,56 92,64 58,35 48,49 45,49 98,53 88,07 95,99 25 0.0 73,58 97,34 44,48 33,05 19,81 99,43 87,15 99,40 27 0.0 76,49 99,55 72,63 46,54 63,97 99,59 95,69 99,57 4.2 Hepatotoxicity test of bispecific antibodies

[0136] The drug's hepatic toxicity and side effects during administration are primarily determined by measuring serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), with higher levels indicating greater liver cell damage. In this experiment, a test kit for alanine aminotransferase (glutamine aminotransferase / ALT / GPT) (Reitmen method) using the microplate method (Nanjing Jiancheng Biotechnology, item number C009-2-1) and a test kit for aspartate aminotransferase (glutamate oxaloacetate transaminase / AST / GOT) were used.

[0137] (Microplate method) (Nanjing Jiancheng Biotechnology, article number C010-2-1) is used, and the specific test methods are as follows: In a 96-well plate, 20 µl of the 37°C pre-warmed matrix solution was added to the test wells, and 5 µl of the mouse serum collected at the end of administration was added to the wells. Mixing was done by gentle shaking. Only 20 µl of the 37°C pre-warmed matrix solution was added to the control wells, also by gentle shaking. The 96-well plate was placed in an incubator at a constant temperature of 37°C for 30 minutes, after which the plate was removed. 20 µL of the 2,4-dinitrophenylhydrazine solution were added to the test wells and mixed by gentle shaking. In the control wells, 20 µL of the 2,4-dinitrophenylhydrazine solution was added first, followed by 5 µL of distilled water. The color development was then carried out by mixing and gentle shaking.The 96-well plate was then placed in a constant-temperature incubator at 37°C for 20 minutes, and 200 µl of 0.4 mol / L NaOH was added to all wells of the 96-well plate. Color development was stopped by gentle shaking and thorough mixing. Finally, the plate was allowed to stand at room temperature for 10 minutes and then sent to an enzyme laboratory for detection (λ=510 nm).

[0138] Blood was drawn from the mice on days 21 and 27 for AST and ALT level testing, and the ALT and AST test results from day 21 are in Fig. 8A-8B and those on the 27th day in Fig.Figures 8C-8D show that the ALT and AST values ​​from the group with bispecific antibodies C8-WT-NA3S-HC and C8-2-NA3S-HC are comparable to those from the PBS group, while the values ​​of the monoclonal selicrelumab antibody control group are 7-8 times higher than those of the bispecific antibody group, indicating that the bispecific antibodies C8-WT-NA3S-HC and C8-2-NA3S-HC obtained by the present invention not only have superior tumor-inhibiting effects and better targeting, but also have no toxic side effects on the liver and are safer than selicrelumab. QUOTES INCLUDED IN THE DESCRIPTION

[0000] This list of documents cited by the applicant was automatically generated and is included solely for the reader's convenience. The list is not part of the German patent or utility model application. The DPMA accepts no liability for any errors or omissions. Cited patent literature

[0000] WO 2005 / 035572

[0039] CN202110577432.9

[0102] CN202110795793.0

[0102] US20120301488A1

[0105] WO2020238730A1 [0111, 0114] DD1204-03 [0118, 0121, 0128, 0131] Cited non-patent literature

[0000] Hassan SB et al. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol 2014; 36:96-104

[0002] Kindt et al. Kuby Immunology, 6th Ed., WHFreeman and Co. Page 91 (2007)

[0034] Chothia et al. (1989) Nature 342: 877-883, Al-Lazikani et al. “Standard conformations for the canonical structures of immunoglobulins”. Journal of Molecular Biology, 273, 927-948 (1997)

[0035] Kabat based on the variability of antibody sequences (Kabat et al, Sequences of Proteins of Immunological Interest, 4th ed., US Dept. of Health and Human Services, National Institutes of Health (1987

[0035] AbM (University of Bath), Contact (University College London), International ImMunoGeneTics Database (IMGT) (http: / / imgt.cines.fr / )

[0035] Algorithm of Needlema and Wunsch ((1970) J. Mol. Biol. 48:444-453) used (available at http: / / www.gcg.com)

[0048] Identity between two nucleotide sequences using the GAP program in the GCG software package (available at http: / / www.gcg.com)

[0048] Algorithm by E. Meyers and W. Miller ((1989) CABIOS, 4:11-17)

[0049]

Claims

[1] A bispecific anti-CD40×CLDN18.2 antibody comprising (i) an anti-CD40 antibody or a fragment thereof, and (ii) an anti-CLDN18.2 antibody or a fragment thereof, wherein the anti-CD40 antibody or fragment thereof comprises three heavy chain CDRs as contained in SEQ ID NO:11, or variants thereof, and three light chain CDRs as contained in SEQ ID NO:10, or variants thereof; the anti-CD40 antibody or fragment thereof comprises three heavy chain CDRs as contained in SEQ ID NO:12, or variants thereof, and three light chain CDRs as contained in SEQ ID NO:10, or variants thereof; the anti-CD40 antibody or fragment thereof comprises three CDRs of the heavy chain as contained in SEQ ID NO:13, or variants thereof, and three CDRs of the light chain as contained in SEQ ID NO:10, or variants thereof; or the anti-CD40 antibody or fragment thereof comprises three heavy chain CDRs as contained in SEQ ID NO:14, or variants thereof, and three light chain CDRs as contained in SEQ ID NO:10, or variants thereof; wherein the variant has one or two amino acid substitutions, additions and / or deletions compared to the sequence from which it is derived. [2] The bispecific antibody of claim 1, wherein the anti-CLDN18.2 antibody or a fragment thereof is a single structural domain antibody (VHH), wherein the single structural domain antibody comprises three CDRs as contained in SEQ ID NO:18, or variants thereof; wherein the variants have one or two amino acid substitutions, additions and / or deletions compared to the sequence from which it is derived. [3] Bispecific antibody according to claim 1 or 2, comprising: (i) a heavy chain with the structure VH-CH1-Fc-VHH, and (ii) a light chain with the structure VL-CL, where the VH comprises three CDRs of the heavy chain as contained in SEQ ID NO:11, the VL comprises three CDRs of the light chain as contained in SEQ ID NO:10, and the VHH comprises three CDRs as contained in SEQ ID NO:18; the VH comprises three CDRs of the heavy chain as contained in SEQ ID NO:12, the VL comprises three CDRs of the light chain as contained in SEQ ID NO:10, and the VHH comprises three CDRs as contained in SEQ ID NO:18; the VH comprises three CDRs of the heavy chain as contained in SEQ ID NO:13, the VL comprises three CDRs of the light chain as contained in SEQ ID NO:10, and the VHH comprises three CDRs as contained in SEQ ID NO:18; or the VH comprises three CDRs of the heavy chain as contained in SEQ ID NO:14, the VL comprises three CDRs of the light chain as contained in SEQ ID NO:10, and the VHH comprises three CDRs as contained in SEQ ID NO:

18. [4] Bispecific antibody according to any one of claims 1 to 3, comprising: (i) a heavy chain with the structure VH-CH1-Fc-VHH, and (ii) a light chain with the structure VL-CL, where the VH comprises three CDRs of the heavy chain as shown in SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, the VL comprises three CDRs of the light chain as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and the VHH comprises three CDRs as shown in SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17; the VH comprises three CDRs of the heavy chain as shown in SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, the VL comprises three CDRs of the light chain as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and the VHH comprises three CDRs as shown in SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17; the VH comprises three CDRs of the heavy chain as shown in SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:8, the VL comprises three CDRs of the light chain as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and the VHH comprises three CDRs as shown in SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17; or the VH comprises three CDRs of the heavy chain as shown in SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:9, the VL comprises three CDRs of the light chain as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and the VHH comprises three CDRs as shown in SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:

17. [5] Bispecific antibody according to any one of claims 1 to 4, wherein the VH comprises a sequence shown in SEQ ID NO:11 or a sequence with at least 90% sequence identity to SEQ ID NO:11, the VL comprises a sequence shown in SEQ ID NO:10 or a sequence with at least 90% sequence identity to SEQ ID NO:10, the VHH comprises a sequence shown in SEQ ID NO:18 or a sequence with at least 90% sequence identity to SEQ ID NO:18; the VH comprises a sequence shown in SEQ ID NO:12 or a sequence with at least 90% sequence identity to SEQ ID NO:12, the VL comprises a sequence shown in SEQ ID NO:10 or a sequence with at least 90% sequence identity to SEQ ID NO:10, the VHH comprises a sequence shown in SEQ ID NO:18 or a sequence with at least 90% sequence identity to SEQ ID NO:18; the VH comprises a sequence shown in SEQ ID NO:13 or a sequence with at least 90% sequence identity to SEQ ID NO:13, the VL comprises a sequence shown in SEQ ID NO:10 or a sequence with at least 90% sequence identity to SEQ ID NO:10, the VHH comprises a sequence shown in SEQ ID NO:18 or a sequence with at least 90% sequence identity to SEQ ID NO:18; or the VH comprises a sequence shown in SEQ ID NO:14 or a sequence with at least 90% sequence identity to SEQ ID NO:14, the VL comprises a sequence shown in SEQ ID NO:10 or a sequence with at least 90% sequence identity to SEQ ID NO:10, the VHH comprises a sequence shown in SEQ ID NO:18 or a sequence with at least 90% sequence identity to SEQ ID NO:

18. [6] Bispecific antibody according to any one of claims 1 to 5, wherein the VHH is linked to the Fc via an adapter, preferably the adapter is (G4S)n, where n is an integer equal to or greater than 1, for example n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, and more preferably the adapter is selected from (G4S)3. [7] A bispecific antibody according to any one of claims 1 to 6, wherein the Fc region is the Fc region of an antibody of the IgG class, eg the Fc region of an IgGl, eg the Fc region of an IgGl with a modification, eg the Fc region of an IgGl with an N297Q mutation. [8] A bispecific antibody according to any one of claims 1 to 7, wherein the constant structural domain CL of the light chain of the antibody is derived from κ or λ. [9] Bispecific antibody according to any one of claims 1 to 8, comprising: (i) a heavy chain with the structure VH-CH1-Fc-VHH, and (ii) a light chain with the structure VL-CL, where the heavy chain comprises a sequence shown in SEQ ID NO:19 or a sequence with at least 90% sequence identity to SEQ ID NO:19, and the light chain comprises a sequence shown in SEQ ID NO:23 or a sequence with at least 90% sequence identity to SEQ ID NO:23; the heavy chain comprises a sequence shown in SEQ ID NO:20 or a sequence with at least 90% sequence identity to SEQ ID NO:20, and the light chain comprises a sequence shown in SEQ ID NO:23 or a sequence with at least 90% sequence identity to SEQ ID NO:23; the heavy chain comprises a sequence shown in SEQ ID NO:21 or a sequence with at least 90% sequence identity to SEQ ID NO:21, and the light chain comprises a sequence shown in SEQ ID NO:23 or a sequence with at least 90% sequence identity to SEQ ID NO:23; or the heavy chain comprises a sequence shown in SEQ ID NO:22 or a sequence with at least 90% sequence identity to SEQ ID NO:22, and the light chain comprises a sequence shown in SEQ ID NO:23 or a sequence with at least 90% sequence identity to SEQ ID NO:

23. [10] A polynucleotide encoding a bispecific antibody according to any one of claims 1 to 9. [11] Vector, preferably an expression vector, containing the polynucleotide according to claim 10. [12] A host cell containing the polynucleotide of claim 10 or the vector of claim 11. [13] A method for producing a bispecific antibody according to any one of claims 1 to 9, comprising the steps of: (i) culturing a host cell of the present invention under conditions suitable for the expression of a bispecific antibody of the present invention, and optionally (ii) recovering the bispecific antibody of the present invention. [14] Immunoconjugates, kits, pharmaceutical compositions, combination products or articles comprising the bispecific antibody of any one of claims 1 to 9. [15] Kit, pharmaceutical composition, combination product or article according to claim 14, which further contains other therapeutic active ingredients and optionally pharmaceutical excipients; preferably the other therapeutic active ingredients are selected from chemotherapeutic active ingredients, cytotoxic active ingredients. [16] Use of the bispecific antibody according to any one of claims 1 to 9, the immunoconjugate, the kit, the pharmaceutical composition, the combination product or the article according to claim 14 or 15 for use in a medicament, kit for the treatment, prevention and / or diagnosis of a CD40-associated disease or a CLDN18.2-associated disease, wherein the CLDN18.2-associated disease is preferably a cancer with abnormal expression of CLDN18.2, wherein the CD40-associated disease is a cancer with abnormal expression of CD40. [17] A method for treating a disease associated with CD40 or for treating a disease associated with CLDN 18.2, comprising administering to a patient in need thereof a therapeutically effective amount of a bispecific antibody according to any one of claims 1 to 9 or the immunoconjugate, pharmaceutical composition, combination product or article according to claim 14 or 15.

Citation Information

Patent Citations

  • Anti-CD40 antibodies and uses thereof

    CN115403670A

  • CLDN18.2 binding molecules and uses thereof

    CN115611983A

  • DD120403A5

  • Anti-CD40 antibodies and methods of use

    US20120301488A1

  • Antibody compositions and methods

    WO2005035572A2